- Home
- / Oncopeptides
Oncopeptides
Stock Price
KR2.1
2024-10-29
Market Capitalization
KR452.1 M
2024-10-29
Revenue
KR71.1 M
FY, 2025
Oncopeptides Summary
Company Summary
- Overview
- Oncopeptides is a clinical development pharmaceutical company. It develops anti-cancer drugs. The Company has created Ygalo, a cytotoxic therapy that is in late-stage development use for the treatment of multiple myeloma.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Stockholm, SE | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
5 locations detected
Stockholm, Stockholms län HQ
Sweden
46 Luntmakargatan
Los Altos, CA
United States
4940 El Camino Real #100
Mountain View, CA
United States
444 Castro St
Waltham, MA
United States
200 5th Ave #1030
Stockholm, Stockholms län
Sweden
Tändstickspalatset, Västra Trädgårdsgatan 15
Oncopeptides Financials
Summary Financials
- Revenue (Q1, 2026)
- kr25.4M
- Gross profit (Q1, 2026)
- kr28.2M
- Net income (Q1, 2026)
- (kr32.2M)
- Cash (Q1, 2026)
- kr205.2M
- EBIT (Q1, 2026)
- (kr37.5M)
- Enterprise value
- $504.3M
Competitors and Similar Companies
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026